Abstract
It is important that the introduction of breast screening is closely monitored. The anticipated effect on breast cancer mortality will take 10 years or more fully to emerge, and will only occur if a succession of more short-term end points are met. Data from the Swedish two-county randomised trial provide targets that should be achieved, following a logical progression of compliance with the initial invitation, prevalence and stage distribution at the prevalence screen, the rate of interval cancers after the initial screen, the pick-up rate and stage distribution at later screening tests, the rate of interval cancers after later tests, the absolute rate of advanced cancer and finally the breast cancer mortality rate. For evaluation purposes, historical data on stage at diagnosis is desirable; it is suggested that tumour size is probably the most relevant variable available in most cases.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Collette H. J., Day N. E., Rombach J. J., de Waard F. Evaluation of screening for breast cancer in a non-randomised study (the DOM project) by means of a case-control study. Lancet. 1984 Jun 2;1(8388):1224–1226. doi: 10.1016/s0140-6736(84)91704-5. [DOI] [PubMed] [Google Scholar]
- Day N. E., Walter S. D. Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics. 1984 Mar;40(1):1–14. [PubMed] [Google Scholar]
- De Bono A. M., Pillers E. M. Carcinoma of the breast in East Anglia 1960-1975: a changing pattern of presentation? J Epidemiol Community Health. 1978 Sep;32(3):178–182. doi: 10.1136/jech.32.3.178. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Palli D., Del Turco M. R., Buiatti E., Carli S., Ciatto S., Toscani L., Maltoni G. A case-control study of the efficacy of a non-randomized breast cancer screening program in Florence (Italy). Int J Cancer. 1986 Oct 15;38(4):501–504. doi: 10.1002/ijc.2910380408. [DOI] [PubMed] [Google Scholar]
- Tabar L., Duffy S. W., Krusemo U. B. Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. Eur J Cancer Clin Oncol. 1987 Jul;23(7):959–962. doi: 10.1016/0277-5379(87)90341-5. [DOI] [PubMed] [Google Scholar]
- Tabár L., Faberberg G., Day N. E., Holmberg L. What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer. 1987 May;55(5):547–551. doi: 10.1038/bjc.1987.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tabár L., Fagerberg C. J., Gad A., Baldetorp L., Holmberg L. H., Gröntoft O., Ljungquist U., Lundström B., Månson J. C., Eklund G. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985 Apr 13;1(8433):829–832. doi: 10.1016/s0140-6736(85)92204-4. [DOI] [PubMed] [Google Scholar]
- Verbeek A. L., Hendriks J. H., Holland R., Mravunac M., Sturmans F., Day N. E. Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. Lancet. 1984 Jun 2;1(8388):1222–1224. doi: 10.1016/s0140-6736(84)91703-3. [DOI] [PubMed] [Google Scholar]
- de Waard F., Collette H. J., Rombach J. J., Baanders-van Halewijn E. A., Honing C. The DOM project for the early detection of breast cancer, Utrecht, The Netherlands. J Chronic Dis. 1984;37(1):1–44. doi: 10.1016/0021-9681(84)90123-1. [DOI] [PubMed] [Google Scholar]